Announcement • May 23
Envoy Medical, Inc. Receives A Second Staff Notification from Nasdaq Informing the Company Is Eligible for an Additional 180 Day Period, Until November 16, 2026, to Meet the Bid Price Requirement As previously disclosed, on November 19, 2025, Envoy Medical, Inc. (the Company), received a staff determination notice (the Notice) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq), informing the Company that its Class A Common Stock, par value $0.0001 per share (the Common Stock), had failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market (the Capital Market) under Nasdaq Listing Rule 5550(a)(2) (the Bid Price Requirement) for the 30 consecutive business days prior to the date of the Notice. The Notice had no immediate effect on the listing of the Common Stock on Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial compliance period of 180 calendar days, or until May 18, 2026 (the Compliance Date), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Common Stock was required to meet or exceed $1.00 per share for a minimum of ten consecutive business days prior to the Compliance Date. On May 19, 2026, the Company received a second staff notification from Nasdaq informing the Company that, although the Company had not met the Bid Price Requirement by the Compliance Date, the Company is eligible for an additional 180 day period, until November 16, 2026, to meet the Bid Price Requirement (the Second Compliance Period). Nasdaq's determination that the Company is eligible for a Second Compliance Period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for listing on the Capital Market with the exception of the bid price requirement and the Company's written notice to Nasdaq of its intention to cure the deficiency during the Second Compliance Period by effecting a reverse stock split, if necessary. Reported Earnings • May 12
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: US$0.083 loss per share (improved from US$0.29 loss in 1Q 2025). Net loss: US$5.70m (loss narrowed 8.6% from 1Q 2025). Revenue missed analyst estimates by 35%. Earnings per share (EPS) exceeded analyst estimates by 43%. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 24
Full year 2025 earnings released: US$1.02 loss per share (vs US$1.49 loss in FY 2024) Full year 2025 results: US$1.02 loss per share (improved from US$1.49 loss in FY 2024). Net loss: US$23.8m (loss narrowed 15% from FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. 
